What CJC-1295 is
CJC-1295 is a stabilized analog of growth-hormone-releasing hormone, and the name is used loosely for two distinct compounds. Without DAC (properly Mod GRF 1-29) it produces a short, sharp GHRH pulse and is dosed like a secretagogue, one to three times daily. With DAC it binds albumin and elevates GH baseline for a week per injection, a different physiological effect (sustained elevation rather than pulses) with different tradeoffs.
The community default is no-DAC paired with ipamorelin in the same syringe, on the logic that a GHRH analog plus a GHRP amplify the same pulse through complementary receptors. Check which version a vendor vial actually is before doing any math; the dosing differs by an order of magnitude.
What we do not know
- The published human data is for CJC-1295 WITH DAC. Most material sold as CJC-1295 is the no-DAC form, whose human evidence is far thinner.
- Phase 1 work showed it raises GH and IGF-1. No trial has tested whether that produces any clinical outcome.
- Not approved anywhere.
Reconstitution math
Concentration is everything: the same 5 mg vial gives a different draw for every amount of bacteriostatic water you add. The table uses the common 2 mL setup for each vial size, which puts every unit on a U-100 insulin syringe at 25 mcg for the default vial. Dashes mark draws too small to measure or larger than the syringe.
| Vial | BAC water | Concentration | 100 mcg | 200 mcg | 300 mcg |
|---|---|---|---|---|---|
| 2 mg | 2 mL | 1 mg/mL | 10 u | 20 u | 30 u |
| 5 mg | 2 mL | 2.5 mg/mL | 4 u | 8 u | 12 u |
| 10 mg | 2 mL | 5 mg/mL | 2 u | 4 u | 6 u |
Dosing and protocol
Community protocol (no DAC): 100 mcg 1 to 3 times daily, almost always paired with ipamorelin; DAC version: about 2 mg once weekly.
For the no-DAC version, community protocols run 100 mcg per injection, one to three times daily, commonly at night. On a 5 mg vial with 2 mL of water, 100 mcg is 4 units. The DAC version is dosed around 2 mg once weekly. The blend calculator handles the combined CJC + ipamorelin draw.
Pharmacokinetics
No curve is shown, on purpose.
The name covers two different molecules. CJC-1295 with DAC has real human pharmacokinetics: a 6 to 8 day half-life from albumin binding (Teichman 2006). The no-DAC version (Mod GRF 1-29), which is what most community protocols mean, has no formal human PK and is expected to clear in well under an hour like other GRF analogs. Plotting either number on a page that covers both would mislead, so neither is plotted.
How it is thought to work
A GHRH analog. The commonly sold version lacks the DAC (drug affinity complex) modification of the compound that was actually trialed, which changes the half-life by orders of magnitude. The two are routinely conflated when sold.
What the evidence supports
This table grades how well each outcome has been studied in humans, not how well CJC-1295 works. A strong grade means the question was asked properly, and the answer may still have been negative. Nothing here is inherited from a drug class, a close analog, or the parent molecule of a fragment.
| Outcome | Strongest published evidence |
|---|---|
| Raises GH and IGF-1 (with DAC) | Human RCT |
| Body composition change | No data |
| Sleep quality | No data |
Storage and handling
Lyophilized vials keep best cold, dark, and dry; refrigeration is the community default and freezing lyophilized powder is common for long holds. After reconstitution, refrigerate at 2 to 8 C, do not freeze the solution, and date the vial. Bacteriostatic water's preservative keeps multi-dose use practical for about 28 days by USP convention, though our 120-day stability study found the preservative itself outlasts that window.
Got a certificate of analysis with your vial? Run it through our COA Reader: it reads the report in plain English, checks purity and mass against the label claim, and links the testing lab’s own verification page. Our guide to reading a COA explains what the numbers do and do not tell you.
Sources
- Teichman et al., Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, J Clin Endocrinol Metab 2006
- Ionescu and Frohman, Pulsatile GH secretion with continuous GHRH analog administration, J Clin Endocrinol Metab 2006